Kiadis Pharma N.V. announced that at its next general meeting of shareholders, the supervisory board will nominate Dr. Robert Soiffer and Berndt Modig to be appointed as new members of the supervisory board. Soiffer is Professor of Medicine at the Harvard Medical School, Chief of the Division of Hematologic Malignancies at the Dana-Farber Cancer Institute (which is part of the Harvard Medical School) and Co-director of the Adult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute. Dr. Soiffer is Chair Elect of the Advisory Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), serves on the Board of Directors for the National Marrow Donor Program Be the Match Registry and has served as President of the American Society of Blood and Marrow Transplantation (ASBMT).

Berndt Modig served as chief financial officer of Prosensa Holding N.V. and as chief financial officer at Jerini AG. Modig is currently serving on the boards of Axovant Sciences Ltd., Auris Medical AG and Affimed N.V. and is CEO of Pharvaris B.V.